Human IGFBP-4 MAb (Clone 82334) (500 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human IGFBP-4 MAb (Clone 82334) (500 UG)

货号： MAB804 基本售价： 5026.6 元规格： 500 ug

产品信息

概述
货号	MAB804
别名	BP-4; HT29-IGFBP; IBP4insulin-like growth factor-binding protein 4; IGF-binding protein 4; IGFBP-4IBP-4; insulin-like growth factor binding protein 4
全称	Insulin-like Growth Factor Binding Protein 4
反应种属	Human
应用	Neutralization
目标/特异性	Detects human IGFBP-4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) IGFBP-1, rhIGFBP-2, or rhIGFBP-3 is observed.
使用方法	Neutralization: Measured by its ability to neutralize IGFBP‑4 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND₅₀) is typically 10‑40 µg/mL in the presence of 0.3 µg/mL Recombinant Human IGFBP‑4 and 14 ng/mL Recombinant Human IGF‑II.
来源	Monoclonal Mouse IgG_2B Clone # 82334
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	3487 (Human); 16010 (Mouse)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A Biochem. Biophys. Res. Commun., 2005;333(3):1011-6. Species: Human Sample Type: recombinant IGFBP-4 Application: WB
纯化方式	Protein A or G purified from ascites
免疫原	Mouse myeloma cell line NS0-derived recombinant human IGFBP‑4 Asp22-Glu258 Accession # AAA62670
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.5 mg/mL in sterile PBS.
背景	Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) precursor protein with a predicted 21 aa signal peptide that is processed to generate the 237 aa mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% aa sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, -4, -5, -6) and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.
运输条件	Blue Ice
存放说明	-20℃
参考文献	Jones, J. I. and D.R. Clemons (1995) Endocrine Rev. 16:3. Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619. Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.

参考图片

IGFBP‑4 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑4 Antibody. Recombinant Human IGFBP‑4 (Catalog # 804-GB) inhibits Recombinant Human IGF‑II (Catalog # 292-G2) induced proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF‑II (14 ng/mL) activity elicited by Recombinant Human IGFBP‑4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP‑4 Monoclonal Antibody (Catalog # MAB804). The ND₅₀is typically 10‑40 µg/mL.